- Company
- Enhertu seeks reimb for HER2-low breast cancer and NSCLC
- by Eo, Yun-Ho Mar 14, 2025 05:56am
- The ADC anticancer drug 'Enhertu' has started a new reimbursement journey in Korea. According to industry sources, Daiichi Sankyo Korea submitted an application to receive reimbursement for two additional indications of its antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) in December last year and recently began discussions w
- Company
- Wegovy dominates the obesity drug market
- by Chon, Seung-Hyun Mar 13, 2025 05:59am
- The introduction of Novo Nordisk's Wegovy has shaken the market substantially. Since its launch in Q4, Wegovy has captured 60% of the entire market. Given the introduction of Wegovy, the obesity market expanded to the largest in history. It also consumed the market for Saxenda, containing the same class of active ingredients as Weogvy. It is unc
- Company
- "High hopes for Blincyto as consolidation therapy for ALL"
- by Whang, byung-woo Mar 13, 2025 05:58am
- Blincyto (blinatumomab), a treatment for acute lymphoblastic leukemia (ALL), is approved for an expanded indication as a consolidation therapy. Its role in clinical settings will be broadened. Experts view that having more treatment options is favorable, as the consolidation therapy option has been limited following the first-line treatment o
- Company
- ‘Keytruda’s 10-year milestones show its core value’
- by Whang, byung-woo Mar 13, 2025 05:58am
- Although many drugs have left their mark on the domestic pharmaceutical market, it is difficult to talk about the last decade without mentioning the immuno-oncology drug, Keytruda (pembrolizumab). As a drug that holds the title of the No. 1 in global sales, it has left various milestones in Korea, from sales to approved indications. Th
- Company
- Emergence of a next-generation lung cancer targeted drug?
- by Son, Hyung Min Mar 12, 2025 05:57am
- Clinical trials on 4th generation non-small-cell lung cancer targeted therapies by domestic and international pharmaceutical and biopharmaceutical companies are progressing smoothly. J INTS BIO, Voronoi, Therapex, and BridgeBio are continuing their development making clinical success. Among global pharmaceutical companies, Blue Diamond has enter
- Company
- New ADC for breast cancer 'Trodelvy' at the final reimb step
- by Eo, Yun-Ho Mar 12, 2025 05:57am
- A new antibody-drug conjugate (ADC) for breast cancer, 'Trodelvy,' will enter the last stage toward being added to the insurance reimbursement list. The Ministry of Health and Welfare (MOHW) ordered the National Health Insurance Service (NHIS) to begin drug pricing negotiations for Gilead Sciences Korea's triple-negative breast cancer (TNB
- Company
- 12 Korean biosimilars globally approved in 3 months
- by Chon, Seung-Hyun Mar 12, 2025 05:56am
- Domestic pharma and biotech companies have achieved 12 biosimilar approvals in the U.S. and Europe this year. Celltrion and Samsung Bioepis have surpassed last year's record of 11 approvals in three months due to their rapid global expansion. Together, Celltrion and Samsung Bioepis have received over 20 biosimilar approvals in Europe and the Uni
- Company
- Besremi demonstrates effects in polycythemia vera
- by Whang, byung-woo Mar 11, 2025 05:54am
- "In polycythemia vera, 10&8211;20% of patients develop resistance or intolerance to hydroxyurea treatment. Since no other treatment option is available, reimbursement for the new treatment option must be considered." Although the average survival for polycythemia vera is around 14.1 years, typically considered a comparatively lower mortality
- Company
- Celltrion’s Xolair biosimilar Omlyclo is approved in the US
- by Chon, Seung-Hyun Mar 11, 2025 05:54am
- Celltrion announced on the 10th that ‘Omlyclo,’ its biosimilar version of ‘Xolair’ has was approved by the US Food and Drug Administration (FDA). Xolair is an antibody biologic used for allergic asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and chronic spontaneous urticaria (CSU). Xolair posted global sales of approximate
- Company
- AbbVie’s Rinvoq to benefit most from changes in KOR
- by Whang, byung-woo Mar 10, 2025 06:05am
- Expansion has been growing on the expansion of related prescription markets with the government approving reimbursement for switching between atopic dermatitis treatments, which has been in high demand in the field. The industry expects an increased number of treatment options and an expanded scope of reimbursement to enable more effective tr
